These benefits, together with a earlier report exhibiting that a little-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,two support the thought of targeting ACKR3 as a unique approach to modulate the opioid procedure, which could open new therapeutic avenues for opioid-rel